BGHL (EUR): NAV(s)
July 17, 2024 01:30 ET
|
BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
BW Energy: Signs Letter Agreement to acquire shares in Reconnaissance Energy Africa and 20% interest in onshore exploration license PEL 73 in Namibia
July 17, 2024 01:30 ET
|
BW Energy Limited
BW Energy: Signs Letter Agreement to acquire shares in Reconnaissance Energy Africa and 20% interest in onshore exploration license PEL 73 in Namibia BW Energy has signed a Letter Agreement...
BGHL (GBP): NAV(s)
July 17, 2024 01:30 ET
|
BOUSSARD AND GAVAUDAN HOLDING LIMITED (GBP)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
TGS Secures Ocean Bottom Node Data Acquisition Contract in North America
July 17, 2024 01:30 ET
|
TGS ASA
OSLO, Norway (17 July 2024) – TGS, a leading global provider of energy data and intelligence, is pleased to announce the award of an Ocean Bottom Node (OBN) data acquisition contract in North America....
McPhy Energy: McPhy completes the disposal of its refueling stations business to Atawey
July 17, 2024 01:30 ET
|
MCPHY ENERGY SA
Emergence of two pure players, among the European leaders in their respective segments and key actors in the hydrogen sector in France;Final sale price was set at €12 million, payable in instalments...
Sampo plc’s share buybacks 16 July 2024
July 17, 2024 01:30 ET
|
Sampo plc
SAMPO PLC STOCK EXCHANGE RELEASE 17 July 2024 at 8:30 am Sampo plc’s share buybacks 16 July 2024 On 16 July 2024, Sampo plc (business code 0142213-3, LEI...
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
July 17, 2024 01:30 ET
|
Orion Oyj
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen...
ONWARD® Medical Publishes Annual Sustainability Summary
July 17, 2024 01:30 ET
|
ONWARD Medical NV
ONWARD® Medical Publishes Annual Sustainability Summary
OKX Ventures Releases Bi-Monthly Investment Report (May-June 2024)
July 17, 2024 01:12 ET
|
OKX
SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- OKX Ventures, the investment arm of leading Web3 technology company OKX, has released its bi-monthly investment report for May-June 2024, highlighting...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
July 17, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001)1 Pharmacokinetic data supports a once-daily oral dosing...